Fundz

Fog Pharmaceuticals, Inc. reported raising $23.3 Million in an initial SEC Form D filing, from an offering of $107 Million

PUBLIC · PBLSJan 05, 2021$23.3M of $107M raised

Amount Raised

$23.3 Million

$23.3 Million sold, per SEC Form D (first sale Jan 5, 2021)

Round Type

Venture

CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Quick answer

Parabilis Medicines raised $23.3 Million in a funding round, dated January 5, 2021. Parabilis Medicines is based in Cambridge, Massachusetts, United States.

How much did Parabilis Medicines raise?
Parabilis Medicines raised $23.3 Million in a funding round on January 5, 2021.
What does Parabilis Medicines do?
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer.
Where is Parabilis Medicines based and how big is it?
Parabilis Medicines is based in Cambridge, Massachusetts, United States. Fundz records about 170 employees.
Who are the decision-makers at Parabilis Medicines?
Fundz holds 1 contact at Parabilis Medicines, including the Chairman, CEO and President. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Parabilis Medicines that raised within 45 days of this round, from Fundz verified event records.

  • ISOThrive raised $5.2M on February 5, 2021.
  • OnKure Therapeutics, Inc. raised $47M on December 21, 2020.
  • Oragenics raised $21M (Series C) on February 12, 2021.
  • Day One Biopharmaceuticals raised $130M (Series B) on February 10, 2021.
  • Citius Pharmaceuticals, Inc. raised $20M on February 1, 2021.
  • Zevra Therapeutics, Inc. raised $31M on January 13, 2021.

Who to call at Parabilis Medicines, and when

A new round usually means Parabilis Medicines is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Parabilis Medicines raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Parabilis Medicines, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Parabilis Medicines. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Parabilis Medicines

Location

30 Acorn Park Drive

Cambridge, Massachusetts, United States

About

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Parabilis Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMathai M., Chairman, CEO and President hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Parabilis Medicines's next move

See what Strategic adds

Parabilis Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.